NRXP - NRx Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Wilmington,
United States
Type: Equity
NRXP price evolution
NRXP
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.59 | $8.9 | $14.97 | $16.51 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $6.88 | $13.09 | $19.79 | $21.76 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $7.32 | $13.11 | $19.81 | $21.78 |
| Current liabilities | ||||
| Accounts payable | $4.63 | $3.63 | $2.21 | $3.78 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $19.05 | $19.33 | $22.62 | $22.06 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $19.05 | $19.33 | $22.62 | $22.06 |
| Shareholders' equity | ||||
| Retained earnings | -$253.15 | -$248.81 | -$242.75 | -$234.04 |
| Other shareholder equity | -$0 | -$0.02 | -$0.02 | $0.11 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.59 | $20.05 | $27.61 | $0 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $6.88 | $25.8 | $32.71 | $0.08 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $5.97 | |||
| Total investments | ||||
| Total assets | $7.32 | $25.82 | $32.73 | $6.05 |
| Current liabilities | ||||
| Accounts payable | $4.63 | $2.08 | $3.69 | $0.61 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $19.05 | $15.59 | $11.92 | $1.26 |
| Long term debt | $2.82 | $2.67 | ||
| Total noncurrent liabilities | $2.67 | |||
| Total debt | ||||
| Total liabilities | $19.05 | $18.41 | $11.92 | $3.94 |
| Shareholders' equity | ||||
| Retained earnings | -$253.15 | -$223 | -$183.24 | -$0.72 |
| Other shareholder equity | -$0 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $9.6 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.14 | |||
| Net income | ||||
| Net income | -$6.98 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $94.42 | $0.91 | $0.71 | $1.01 |
| Operating income | -$0.91 | -$0.71 | ||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.02 | $0.08 | $0.02 | |
| Interest expense | $1.67 | $1.09 | ||
| Net income | ||||
| Net income | -$93.06 | -$1.09 | $0.41 | $0.07 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.01 | -$0.01 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $22.09 | $22.12 | $22.98 | $63.46 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$9.36 | -$3.06 | $12.6 | $25.75 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Net income | -$1.09 | $0.41 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$0.6 | -$0.79 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.01 | $26.18 | $40.25 | -$0.65 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $63.46 | -$25.58 | -$39.46 | $0.68 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $25.75 | $0 | -$0.01 | -$0.44 |
News
Fundamentals
| Market cap | $261.83M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 83.92M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.05 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.36 |
| Quick ratio | N/A |